The application relates to a compound of Formula (I′) or (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

The application relates to a compound of Formula (I′) or (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

This disclosure pertains to the preparation of bifunctional compounds (e.g., Compound 1), intermediates in the preparation of such compounds, and preparation of such intermediates.

##STR00001##

The present invention generally relates to new compounds for therapeutic uses. In particular, the disclosed series compounds with immunomodulatory activities are useful for treatment of dysfunctions of the immune system and various cancers. Pharmaceutical composition matters and methods for treating a patient with an immune disease and/or a cancer by administering therapeutically effective amounts of such compound alone or together with other therapeutics are within the scope of this disclosure.

The present invention generally relates to new compounds for therapeutic uses. In particular, the disclosed series compounds with immunomodulatory activities are useful for treatment of dysfunctions of the immune system and various cancers. Pharmaceutical composition matters and methods for treating a patient with an immune disease and/or a cancer by administering therapeutically effective amounts of such compound alone or together with other therapeutics are within the scope of this disclosure.

The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

##STR00001##

Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.

##STR00001##

A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I):

##STR00001##

[in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R.sup.1 and R.sup.2 each independently represents a linear hydrocarbon group that may have —CO—O—; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R.sup.3 and R.sup.4 each independently represents a C.sub.1-4 alkyl group or a C.sub.2-4 alkenyl group, where, R.sup.3 and R.sup.4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C.sub.1-4 alkyl groups or C.sub.2-4 alkenyl groups may be substituted on the ring)].

A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I):

##STR00001##

[in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R.sup.1 and R.sup.2 each independently represents a linear hydrocarbon group that may have —CO—O—; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R.sup.3 and R.sup.4 each independently represents a C.sub.1-4 alkyl group or a C.sub.2-4 alkenyl group, where, R.sup.3 and R.sup.4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C.sub.1-4 alkyl groups or C.sub.2-4 alkenyl groups may be substituted on the ring)].

The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.